Evidence map›Paper›PMID 23304015›Full record

ReviewTexas Heart Institute journal2012

Extreme thrombocytosis and cardiovascular surgery: risks and management.

Ethan A Natelson

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in Texas Heart Institute journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ethan A NatelsonDepartment of Academic Medicine, Weill-Cornell Medical College, and The Methodist Hospital, Houston, Texas 77030, USA. enatelson@tmhs.org
Cornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extreme thrombocytosis is a major risk factor for excessive bleeding and for thrombosis, either of which can complicate cardiovascular surgical and interventional procedures. Extreme thrombocytosis can also cause an unusual syndrome, erythromelalgia, that results in a type of chronic microvascular occlusive arterial disease. We present the differential diagnosis of conditions that may lead to extreme thrombocytosis, 3 cases (each of which illustrates a different potential complication), and a review of the pertinent medical literature. Correcting excessive thrombocytosis is typically not difficult, whether electively or acutely, and effective therapy usually controls thrombosis and excessive hemorrhage post-procedurally.

Indexed as

Cardiovascular Surgical ProceduresThrombocytosisAdultAgedDiagnosis, DifferentialFemaleHumansImmunosuppressive AgentsMaleMiddle AgedPlatelet Aggregation InhibitorsPlateletpheresisPostoperative HemorrhageRisk FactorsThrombosisImmunosuppressive AgentsPlatelet Aggregation InhibitorsCoronary thrombosis/prevention & control/surgeryerythromelalgiahemorrhage/drug therapyhydroxyurea/therapeutic usemyeloproliferative disorders/genetics/pathologyplateletpheresispolycythemia vera/bloodpreoperative care/methodsrisk factorsthrombocythemia, essential/complications/diagnosis/etiology/genetics/metabolism/physiopathology

Identifiers

PMID23304015
PMCPMC3528235
OpenAlexW1549624017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.